Tobramycin for Inhalation ( DrugBank: Tobramycin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	3

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00794586 (ClinicalTrials.gov)	November 2008	18/11/2008	Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection	A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa	Cystic Fibrosis	Drug: FTI, AZLI;Drug: Placebo, AZLI	Gilead Sciences	NULL	Completed	18 Years	N/A	Both	120	Phase 2	United States
2	NCT01400750 (ClinicalTrials.gov)	August 2001	18/7/2011	Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis	Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.	Cystic Fibrosis	Drug: oral ciprofloxacin plus inhaled colistin;Drug: TOBI	Universitaire Ziekenhuizen Leuven	NULL	Completed	N/A	18 Years	Both	61	Phase 4	Belgium
3	NCT00006280 (ClinicalTrials.gov)	February 2000	11/9/2000	A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	Cystic Fibrosis	Drug: Tobramycin for Inhalation	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	National Center for Research Resources (NCRR)	Completed	6 Months	5 Years	Both	98	Phase 2	United States